In a periodic update, Pfizer presented a positive outlook for some of its drugs entering late-stage development, including a JAK inhibitor for rheumatoid arthritis, Alzheimer's disease drug Dimebon and Tanezumab, a monoclonal antibody to treat pain. In a separate announcement, the company said it is halting a trial of Sutent after the cancer medicine failed to outperform chemotherapy drug capecitabine in improving patients' condition.

Related Summaries